DRI gets royalty on CELG's Thalomid

Drug Royalty (TSE:DRI) acquired a royalty interest in worldwide sales of Thalomid thalidomide from Celgene (CELG) for C$4.7 million (US$3 million). DRI said the term of the agreement is tied to U.S. p...